Acceleron Pharma Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Acceleron Pharma Inc (XLRN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Acceleron Pharma Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 113M vs 315M combined for its competitors (26.4% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+21.3% annualized vs trailing 12 months), vs decelerating (-90.5%) for its tracked peer group.
- Growth: Acceleron Pharma Inc generated 51.6% revenue growth year over year in Q3 2021, vs -88.1% for its competitors combined.
- Profitability: Its -206.0% net margin compares with -1,339.1% for the peer group.
- Peer revenue share: Acceleron Pharma Inc accounted for 82.0% of combined revenue among its tracked peer group, up from 26.4% a year earlier.
- Peer differentiation: Revenue per employee of $0.25M compares with $0.59M for the peer group (0.4x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
XLRN Sales vs. its Competitors, Q3 2021
Acceleron Pharma Inc reported revenue growth of 51.58 % year on year in Q3 2021, above its competitors' combined revenue change of -88.09 %.
With a net margin of -206.04 %, Acceleron Pharma Inc achieved higher profitability than its competitors (-1,339.10 %).
Acceleron Pharma Inc generated 82.00 % of the combined sales of its peer group, up from 26.36 % a year earlier.
API endpoints for this dataset
Acceleron Pharma Inc vs. its Competitors, Q3 2021
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Acceleron Pharma Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Acceleron Pharma Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Acceleron Pharma inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (115) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Acceleron Pharma Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 21.9% year over year, combined, vs 51.6% for Acceleron Pharma Inc. Acceleron Pharma Inc's share of combined industry revenue moved from 0.06% to 0.08%, a gain of 0.01 percentage points.
Acceleron Pharma Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Acceleron Pharma inc | - | Yes | No | Yes |
| Competitors combined (5) | - | |||
| High-Confidence Competitors (131) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
XLRN Stock Performance relative to its Competitors
XLRN Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Trevi Therapeutics Inc | 282.9% | Outperformed |
| 2 | Summit Therapeutics Inc | 282.9% | Outperformed |
| 3 | Editas Medicine Inc | 282.9% | Outperformed |
| 4 | Inozyme Pharma Inc | 282.9% | Outperformed |
| 5 | Keros Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Acceleron Pharma Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Acceleron Pharma inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Acceleron Pharma inc |
10,892.49 | 112.76 |
 Summit Therapeutics Inc |
11,710.63 | 2.08 |
 Trevi Therapeutics Inc |
2,132.92 | - |
 Inozyme Pharma Inc |
257.11 | - |
 Editas Medicine Inc |
255.29 | 47.01 |
 Keros Therapeutics Inc |
199.59 | 265.45 |
| SUBTOTAL | 25,448.04 | 427.30 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Acceleron Pharma inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Acceleron Pharma Inc's Competitors Named by the Company
Competitive relationships identified from Acceleron Pharma Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Novartis International AG | Company report | 85% |
| AstraZeneca plc | Company report | 85% |
| Keros Therapeutics Inc | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Pfizer Inc. | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Bayer AG | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Propanc Biopharma Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Petvivo Holdings Inc | Company report | 85% |
| Liminatus Pharma Inc | Company report | 85% |
| Curanex Pharmaceuticals Inc | Company report | 85% |
| Quantum si Incorporated | Company report | 85% |
| Bicara Therapeutics Inc | Company report | 85% |
| Tenax Therapeutics Inc | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Chemomab Therapeutics Ltd | Company report | 85% |
| Trevi Therapeutics Inc | Company report | 85% |
| Personalis Inc | Company report | 85% |
| Enanta Pharmaceuticals Inc | Company report | 85% |
| Ernexa Therapeutics Inc | Company report | 85% |
| BGNE | Company report | 85% |
| Smartkem Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Abivax Sa | Company report | 85% |
| Agomab Therapeutics Nv | Company report | 85% |
| Palatin Technologies Inc | Company report | 85% |
| Elanco Animal Health Incorporated | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
| Sunshine Biopharma Inc | Company report | 85% |
| Oragenics Inc | Company report | 85% |
| Terns Pharmaceuticals Inc | Company report | 85% |
| Absci Corp | Company report | 85% |
| Vaxcyte Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Qnity Electronics Inc | Company report | 85% |
| Mangoceuticals Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Bnb Plus Corp | Company report | 85% |
| Northwest Biotherapeutics Inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| Puretech Health Plc | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
| Maia Biotechnology Inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Altimmune inc | Company report | 85% |
| Scynexis Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Beone Medicines Ltd | Company report | 85% |
| Inhibrx Biosciences Inc | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Pelthos Therapeutics Inc | Company report | 85% |
| Boehringer Ingelheim GmbH | Company report | 85% |
| Dynavax Technologies Corporation | Company report | 85% |
| Invo Fertility Inc | Company report | 85% |
| Actuate Therapeutics Inc | Company report | 85% |
| Pyxis Oncology Inc | Company report | 85% |
| Dupont De Nemours Inc | Company report | 85% |
| NAYA | Company report | 85% |
| Optinose Inc | Company report | 85% |
| INVO | Company report | 85% |
| Cell Source Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Coya Therapeutics Inc | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| Nanoviricides inc | Company report | 85% |
| CHRO | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Sonnet Biotherapeutics Holdings Inc | Company report | 85% |
| Nascent Biotech Inc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Vaccinex Inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Mural Oncology Plc | Company report | 85% |
| Instil Bio Inc | Company report | 85% |
| ENTO | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Cidara Therapeutics Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Gri Bio Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Vaxxinity Inc | Company report | 85% |
| Ayala Pharmaceuticals Inc | Company report | 85% |
| Entegris Inc | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Gridai Technologies Corp | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Biorestorative Therapies Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Immutep Limited | Company report | 85% |
| Seagen Inc | Company report | 85% |
| Novavax inc | Company report | 85% |
| Theriva Biologics inc | Company report | 85% |
| Atreca inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Twist Bioscience Corporation | Company report | 85% |
| Lineage Cell Therapeutics Inc | Company report | 85% |
| Ridgeback Biotherapeutics LP | Company report | 85% |
| Kronos Bio Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Agile Therapeutics Inc | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| Arbutus Biopharma Corp | Company report | 85% |
| Centessa Pharmaceuticals Plc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Scholar Rock Holding Corp | Company report | 85% |
| Aim Immunotech Inc | Company report | 85% |
| Cytodyn inc | Company report | 85% |
| Enveric Biosciences Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Better Therapeutics Inc | Company report | 85% |
| Carisma Therapeutics Inc | Company report | 85% |
| Palisade Bio Inc | Company report | 85% |
| Essa Pharma inc | Company report | 85% |
| Alector Inc | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| Lumos Pharma Inc | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Anavex Life Sciences Corp | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Bio techne Corp | Company report | 85% |
| Achieve Life Sciences Inc | Company report | 85% |
| Urogen Pharma Ltd | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Vertex Inc | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Zoetis Inc | Company report | 85% |
| Sanofi | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Exelixis Inc | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Myovant Sciences Ltd | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Baxter International Inc | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
| Tiziana Life Sciences Ltd | Company report | 85% |
| Affimed N v | Company report | 85% |
| Phibro Animal Health Corporation | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Fortress Biotech Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Bolt Biotherapeutics Inc | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Lianbio | Company report | 85% |
Company report basis, confidence, active dates and source counts for Acceleron Pharma Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Acceleron Pharma Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Editas Medicine Inc | Reportable 100.00 % |
| Keros Therapeutics Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Acceleron Pharma Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Acceleron Pharma inc | 10,892 | 250,584 | -566,338 |
| Summit Therapeutics Inc | 11,711 | 7,864 | -3,230,525 |
| Trevi Therapeutics Inc | 2,133 | - | -1,503,147 |
| Inozyme Pharma Inc | 257 | - | -1,592,776 |
| Editas Medicine Inc | 255 | 540,287 | -849,989 |
| Keros Therapeutics Inc | 200 | 3,403,192 | -1,066,141 |
| PEERS TOTAL | 14,556 | 592,350 | -2,205,311 |
Acceleron Pharma Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (159 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 35.21 % (avg) | -35.2 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -1.12 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 4.61 % | 8.47 % (avg) | -3.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Acceleron Pharma Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.7x | - |
| EV / EBITDA | - | 16.7x | - |
| P/B | 10.1x | 5.1x | +5.0x |
| Return on Equity | -32.39 % | industry aggregate | -56.45 % |
| Return on Invested Capital | -16.09 % | -11.27 % (avg) | -4.82 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Acceleron Pharma Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Revenue Growth | 23.68 % | 53.46 % | -51.46 % | 3.78 % | 428.86 % | 25.04 % |
| Operating Margin | -336.40 % | -238.04 % | -815.84 % | - | - | - |
| Return on Invested Capital | -21.64 % | -13.41 % | -19.41 % | -19.06 % | -13.83 % | -12.76 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Acceleron Pharma Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 4.61 % vs industry average 8.47 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Acceleron Pharma Inc's dedicated Suppliers and Customers pages, not here.
Acceleron Pharma Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+21.3% annualized vs trailing 12 months).
Weaknesses
- Return on equity 56.5 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-90.5% annualized).
Methodology: see Methodology: SWOT Analysis.
Acceleron Pharma Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Acceleron Pharma inc | 7.93 | 13.43 | - |
| Summit Therapeutics Inc | 0.35 | 7.09 | - |
| Trevi Therapeutics Inc | 4.32 | 25.74 | - |
| Inozyme Pharma Inc | 0.78 | 4.60 | 0.60 |
| Editas Medicine Inc | 2.86 | 3.18 | 1.52 |
| Keros Therapeutics Inc | 21.87 | 22.91 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Acceleron Pharma Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Acceleron Pharma inc | Q3 2021 | +51.6 % | - |
| Summit Therapeutics Inc | Q2 2026 | - | - |
| Trevi Therapeutics Inc | Q2 2026 | - | - |
| Inozyme Pharma Inc | Q1 2025 | - | - |
| Editas Medicine Inc | Q2 2026 | +232.3 % | - |
| Keros Therapeutics Inc | Q2 2026 | - | - |
| PEERS TOTAL | +4.0 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Acceleron Pharma Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Acceleron Pharma inc | Q3 2021 | - | +172.8 % |
| Summit Therapeutics Inc | Q2 2026 | - | - |
| Trevi Therapeutics Inc | Q2 2026 | - | - |
| Inozyme Pharma Inc | Q1 2025 | - | - |
| Editas Medicine Inc | Q2 2026 | - | - |
| Keros Therapeutics Inc | Q2 2026 | - | -78.5 % |
Acceleron Pharma Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Acceleron Pharma inc | - | - | - |
| Summit Therapeutics Inc | - | - | - |
| Trevi Therapeutics Inc | - | - | - |
| Inozyme Pharma Inc | - | - | - |
| Editas Medicine Inc | - | - | - |
| Keros Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Acceleron Pharma Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Acceleron Pharma inc | - | 96.60 |
| Summit Therapeutics Inc | - | 5,619.31 |
| Trevi Therapeutics Inc | - | - |
| Inozyme Pharma Inc | - | - |
| Editas Medicine Inc | - | 5.43 |
| Keros Therapeutics Inc | - | 0.75 |
| PEERS AVERAGE | - | 59.56 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.